

## **Supplementary material**

**Journal: Clinical Drug Investigation**

**Open-label study to assess the efficacy of ipragliflozin for reducing insulin dose in patients with type 2 diabetes mellitus receiving insulin therapy**

Hisamitsu Ishihara<sup>1</sup>, Susumu Yamaguchi<sup>2</sup>, Toshifumi Sugitani<sup>2</sup>, Yoshinori Kosakai<sup>2</sup>

<sup>1</sup>Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine, 30-1 Oyaguchikami-cho, Itabashi-ku, Tokyo 173-8610, Japan

<sup>2</sup>Astellas Pharma Inc., 2-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8411, Japan

### **Corresponding author:**

Hisamitsu Ishihara, MD, PhD

Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine  
30-1 Oyaguchikami-cho, Itabashi-ku, Tokyo 173-8610, Japan

Tel: +81-3-3972-8111

Fax: +81-3-3972-8245

E-mail: [ishihara.hisamitsu@nihon-u.ac.jp](mailto:ishihara.hisamitsu@nihon-u.ac.jp)

## **Online Resource 1**

### **List of participating sites**

Tokyo-Eki Center-Building Clinic, Tokyo, Japan

Wakakusa Clinic, Tochigi, Japan

Yokkaichi Diabetes Clinic, Mie, Japan.

KYOSOKAI AMC Nishiumeda Clinic, Osaka, Japan

Utsunomiya Memorial Hospital, Tochigi, Japan

Kunitachi Naika Clinic, Tokyo, Japan

Kikuchi Naika Clinic, Gunma, Japan

Nippon Kokan Fukuyama Hospital, Hiroshima, Japan

Watanabe Naika Clinic, Hyogo, Japan

Okinawa Tokushukai Shonan Kamakura General Hospital, Kanagawa, Japan

HDC Atlas Clinic, Tokyo, Japan


Seiwakai Seiwa Clinic, Tokyo, Japan

Oyama East Clinic, Tochigi, Japan

Tokyo Center Clinic, Tokyo, Japan

Otsu Municipal Hospital, Shiga, Japan

# Online Resource 2 Patient Disposition



<sup>a</sup>Patients who provided informed consent but discontinued before registration were considered screening failures.

<sup>b</sup>Serum creatinine level exceeded 1.5 times the baseline value and exceeded 2.0 mg/dL (176.80 µmol/L).

## Online Resource 3

### Demographic and baseline characteristics of the study population.

	Ipragliflozin 50 mg (n = 103)
Sex, male	75 (72.8)
Age, years	59.0 ± 8.1
Duration of diabetes mellitus, months	162.6 ± 86.7
Body weight, kg	73.92 ± 13.35
Height, cm	165.76 ± 8.30
BMI, kg/m <sup>2</sup>	26.76 ± 3.25
Waist circumference, cm	92.88 ± 9.32
SBP, mmHg	134.1 ± 16.2
DBP, mmHg	77.8 ± 9.9

HbA1c, mmol/mol	59.7 ± 5.6
HbA1c, %	7.62 ± 0.51
Fasting plasma glucose, mmol/L	7.17 ± 1.89
Fasting plasma glucose, mg/dL	129.2 ± 34.1
C-peptide, nmol/L	0.42 ± 0.29
C-peptide, ng/mL	1.255 ± 0.878
eGFR, mL/min/1.73 m <sup>2</sup>	80.7 ± 19.5
< 30	0
30 to < 60	15 (14.6)
60 to < 90	56 (54.4)
≥ 90	32 (31.1)
Total insulin dose, units/day	23.0 ± 12.6
< 15	37 (35.9)
15 to < 30	39 (37.9)
≥ 30	27 (26.2)
Use of other oral antihyperglycemic agents <sup>a</sup>	
Metformin	61 (59.2)
DPP-4 inhibitors	59 (57.3)
α-Glucosidase inhibitors	6 (5.8)
Thiazolidinedions	3 (2.9)

---

Values are presented as n (%) or mean ± standard deviation.

<sup>a</sup>It was prohibited to use SUs, glinides, GLP-1 receptor agonists and insulin products other than long-acting insulin.

Abbreviations:

BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin;; SBP, systolic blood pressure.